ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Haihe Biopharma, Beijing Biotech and Chipscreen Biosciences side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Haihe Biopharma×Beijing Biotech×Chipscreen Biosciences×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Haihe BiopharmaBeijing BiotechChipscreen Biosciences
studies on the registry203242
open to participants now43211
phase 3 studies under way004
reach primary completion within a year0313
programswith a study of their own in two years3406

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseHaihe BiopharmaBeijing BiotechChipscreen Biosciences
Phase 100%

Beijing Biotech: 1 of its 40 programs at phase 1

  1. ETB-DualNK-01phase 1
3%

Chipscreen Biosciences: 2 of its 6 programs at phase 1

  1. CS08399phase 1
  2. CS231295phase 1
33%
Phase 2

Haihe Biopharma: 2 of its 3 programs at phase 2

  1. risovalisibphase 2
  2. EZH1/2 Inhibitor HH2853phase 2
67%

Beijing Biotech: 39 of its 40 programs at phase 2

  1. Cyclophosphamidephase 2
  2. fludarabinephase 2
  3. Dual-target CAR-NK cellsphase 2
  4. ebnk-1822h2 dual-target cldn18.2phase 2
  5. Lymphodepleting chemotherapyphase 2

and 34 more — sign in to see them all

98%

Chipscreen Biosciences: 1 of its 6 programs at phase 2

  1. CS32582phase 2
17%
Phase 3

Haihe Biopharma: 1 of its 3 programs at phase 3

  1. E-3810phase 3
33%
00%

Chipscreen Biosciences: 3 of its 6 programs at phase 3

  1. chiauranibphase 3
  2. tucidinostatphase 3
  3. chiglitazarphase 3
50%
Approved, new studies00%00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Haihe Biopharma0 readouts · 0 phase 3············
Beijing Biotech40 readouts · 0 phase 3···

Beijing Biotech, Feb ’27: 11 programs whose next study reaches primary completion

  1. Dual-target CAR-NK cellsphase 2 · Feb 14 · NCT07467863
  2. Dual-target CAR-NK cells (EB-DT-CAR-NK)phase 2 · Feb 14 · NCT07486089
  3. EB-DART-NK01phase 2 · Feb 14 · NCT07744256
  4. EB-DART-NK01 (DLL3/CD56 CAR-NK cells)phase 2 · Feb 14 · NCT07480213
  5. EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)phase 2 · Feb 14 · NCT07480928

and 6 more — sign in to see them all

Beijing Biotech, Mar ’27: 21 programs whose next study reaches primary completion

  1. Autologous Anti-CD19 CAR-expressing T Lymphocytesphase 2 · Mar 14 · NCT07523542
  2. Autologous BCMA/CD19 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555
  3. Autologous BCMA/CD38 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555
  4. Autologous BCMA/GPRC5D dual-target CAR-Tphase 2 · Mar 14 · NCT07523555
  5. Autologous CD19/CD20 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555

and 16 more — sign in to see them all

Beijing Biotech, Apr ’27: 3 programs whose next study reaches primary completion

  1. Autologous dual-target CAR-T cells selected from the predefined target library.phase 2 · Apr 14 · NCT07523529
  2. eb-701phase 2 · Apr 14 · NCT07551349
  3. EB-701/CA9-NKphase 2 · Apr 14 · NCT07551349
·

Beijing Biotech, Jun ’27: 5 programs whose next study reaches primary completion

  1. AP 1903 reagentphase 2 · Jun 14 · NCT07598955
  2. EB-CAR30-NKphase 2 · Jun 14 · NCT07598955
  3. EB-CAR5-NKphase 2 · Jun 14 · NCT07598955
  4. EB-CARMSLN-NKphase 2 · Jun 14 · NCT07598955
  5. EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cellsphase 2 · Jun 14 · NCT07627698
····
Chipscreen Biosciences2 readouts · 0 phase 3···

Chipscreen Biosciences, Feb ’27: 1 program whose next study reaches primary completion

  1. chiauranibphase 3 · Feb 28 · NCT06492915
······

Chipscreen Biosciences, Sep ’27: 1 program whose next study reaches primary completion

  1. CS32582phase 2 · Sep 18 · NCT07129382
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Haihe Biopharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Beijing Biotech

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Chipscreen Biosciences

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 10 in all. A program counts in each condition its studies name most.

ConditionHaihe BiopharmaBeijing BiotechChipscreen Biosciences
Carcinoma, Non-Small-Cell Lungall three · compare here

Haihe Biopharma in Carcinoma, Non-Small-Cell Lung: 1 program

  1. E-3810phase 3

Their studies: Haihe Biopharma’s studies of Carcinoma, Non-Small-Cell Lung in search

Beijing Biotech in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Cyclophosphamidephase 2
  2. Dual-target CAR-NK cellsphase 2

Their studies: Beijing Biotech’s studies of Carcinoma, Non-Small-Cell Lung in search

Chipscreen Biosciences in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. tucidinostatphase 3
  2. CS08399phase 1

Their studies: Chipscreen Biosciences’ studies of Carcinoma, Non-Small-Cell Lung in search

Small Cell Lung Carcinomaall three · compare here

Haihe Biopharma in Small Cell Lung Carcinoma: 1 program

  1. E-3810phase 3

Their studies: Haihe Biopharma’s studies of Small Cell Lung Carcinoma in search

Chipscreen Biosciences in Small Cell Lung Carcinoma: 1 program

  1. chiauranibphase 3

Their studies: Chipscreen Biosciences’ studies of Small Cell Lung Carcinoma in search

Breast Neoplasmsall three · compare here

Haihe Biopharma in Breast Neoplasms: 1 program

  1. E-3810phase 3

Their studies: Haihe Biopharma’s studies of Breast Neoplasms in search

Beijing Biotech in Breast Neoplasms: 1 program

  1. Cyclophosphamidephase 2

Their studies: Beijing Biotech’s studies of Breast Neoplasms in search

Chipscreen Biosciences in Breast Neoplasms: 1 program

  1. tucidinostatphase 3

Their studies: Chipscreen Biosciences’ studies of Breast Neoplasms in search

Neoplasms2 of 3 · compare here–

Beijing Biotech in Neoplasms: 4 programs

  1. Lymphodepleting chemotherapyphase 2
  2. Cytokine supportphase 2
  3. EB-PT-CAR-NK-Dphase 2
  4. EB-PT-CAR-NK-Sphase 2

Their studies: Beijing Biotech’s studies of Neoplasms in search

Chipscreen Biosciences in Neoplasms: 1 program

  1. CS231295phase 1

Their studies: Chipscreen Biosciences’ studies of Neoplasms in search

Thymoma2 of 3 · compare here

Haihe Biopharma in Thymoma: 1 program

  1. E-3810phase 3

Their studies: Haihe Biopharma’s studies of Thymoma in search

Beijing Biotech in Thymoma: 4 programs

  1. AP 1903 reagentphase 2
  2. EB-CAR30-NKphase 2
  3. EB-CAR5-NKphase 2
  4. EB-CARMSLN-NKphase 2

Their studies: Beijing Biotech’s studies of Thymoma in search

–
Lymphoma, Non-Hodgkin2 of 3 · compare here–

Beijing Biotech in Lymphoma, Non-Hodgkin: 1 program

  1. fludarabinephase 2

Their studies: Beijing Biotech’s studies of Lymphoma, Non-Hodgkin in search

Chipscreen Biosciences in Lymphoma, Non-Hodgkin: 2 programs

  1. chiauranibphase 3
  2. tucidinostatphase 3

Their studies: Chipscreen Biosciences’ studies of Lymphoma, Non-Hodgkin in search

Triple Negative Breast Neoplasms2 of 3 · compare here–

Beijing Biotech in Triple Negative Breast Neoplasms: 2 programs

  1. Dual-target CAR-NK cellsphase 2
  2. Dual-target CAR-NK cells (EB-DT-CAR-NK)phase 2

Their studies: Beijing Biotech’s studies of Triple Negative Breast Neoplasms in search

Chipscreen Biosciences in Triple Negative Breast Neoplasms: 1 program

  1. chiauranibphase 3

Their studies: Chipscreen Biosciences’ studies of Triple Negative Breast Neoplasms in search

Colorectal Neoplasms2 of 3 · compare here

Haihe Biopharma in Colorectal Neoplasms: 1 program

  1. E-3810phase 3

Their studies: Haihe Biopharma’s studies of Colorectal Neoplasms in search

Beijing Biotech in Colorectal Neoplasms: 1 program

  1. EB-DUO-CAR-NK-CEA/GCCphase 2

Their studies: Beijing Biotech’s studies of Colorectal Neoplasms in search

–
Lymphoma, T-Cell, Peripheral2 of 3 · compare here

Haihe Biopharma in Lymphoma, T-Cell, Peripheral: 1 program

  1. EZH1/2 Inhibitor HH2853phase 2

Their studies: Haihe Biopharma’s studies of Lymphoma, T-Cell, Peripheral in search

–

Chipscreen Biosciences in Lymphoma, T-Cell, Peripheral: 1 program

  1. tucidinostatphase 3

Their studies: Chipscreen Biosciences’ studies of Lymphoma, T-Cell, Peripheral in search

Ovarian Neoplasms2 of 3 · compare here

Haihe Biopharma in Ovarian Neoplasms: 1 program

  1. risovalisibphase 2

Their studies: Haihe Biopharma’s studies of Ovarian Neoplasms in search

–

Chipscreen Biosciences in Ovarian Neoplasms: 1 program

  1. chiauranibphase 3

Their studies: Chipscreen Biosciences’ studies of Ovarian Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Haihe Biopharma 2 of 3 · Beijing Biotech 1 of 40 · Chipscreen Biosciences 2 of 6 programs (5 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.